Recombinant human erythropoietin-CTP fusion protein (Harbin Pharmaceutical)

重组人促红素-CTP融合蛋白注射液（哈药集团）

Report date: 2022/07/07 10:52:47

Base Information

Drug NameRecombinant human erythropoietin-CTP fusion protein (Harbin Pharmaceutical)
Drug Alias Name重组人促红素-CTP融合蛋白注射液(CHO细胞)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbin Pharmaceutical Group Holding Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHarbin Pharmaceutical Group Holding Co Ltd
Inactive CompaniesHarbin Pharmaceutical Group R&D Center
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A